Version July 2025
| Patients with active disease |
| Every 3 to 6 months |
| ROS including fever, fatigue, weight loss, visual disturbance, dyspnea, cough, palpitations, abdominal pain, numbness, tingling, lightheadedness, syncope |
| PE including skin examination, palpation of lymph nodes, lung examination |
| Laboratory tests based on sites of disease activity and medications |
| Spirometry and diffusing capacity, for patients with known lung impairment |
| Every 12 months |
| CBC and differential |
| Creatinine |
| Calcium |
| AST, ALT, Alkaline phosphatase |
| 25 hydroxy vitamin D and 1,25 dihydroxy vitamin D, for patients with a history of calcium derangements or bone density abnormalities |
| Chest radiograph |
| As indicated by symptoms or other tests |
| HRCT |
| ECG |
| Echocardiogram |
| Holter monitoring |
| Cardiac MRI |
| Ophthalmologic examination, for patients on hydroxychloroquine or with visual symptoms |
| Urinalysis |
| TSH |
| Bone density (when glucocorticoid therapy initiated and then every 3 years) |
| MRI with gadolinium, for those with neurologic symptoms |
| Patients with inactive disease for 2 or more years |
| Every 12 to 18 months |
| ROS including fever, fatigue, weight loss, visual disturbance, rash, dyspnea, cough, palpitations, abdominal pain, numbness, tingling, lightheadedness, syncope |
| PE including skin examination, palpation of lymph nodes, lung examination |
| Spirometry, diffusing capacity |
| CBC and differential |
| Creatinine |
| Calcium |
| Liver enzymes |
